1] Department of Pathology, Mount Sinai Icahn School of Medicine, New York, NY, USA [2] Columbia University College of Physicians and Surgeons, New York, NY, USA.
Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Oncogene. 2014 Sep 4;33(36):4451-63. doi: 10.1038/onc.2013.411. Epub 2013 Oct 7.
Acquired resistance has curtailed cancer survival since the dawn of the chemotherapy age more than half a century ago. Although the application of stem cell (SC) concepts to cancer captured the imagination of scientists for many years, only the last decade has yielded substantial evidence that cancer SCs (CSCs) contribute to chemotherapy resistance. Recent studies suggest that the functional and molecular properties of CSCs constitute therapeutic opportunities to improve the efficacy of chemotherapy. Here we review how these properties have stimulated combination strategies that suppress acquired resistance across a spectrum of malignancies. The clinical implementation of these strategies promises to rejuvenate the effort against an enduring challenge.
获得性耐药性自半个多世纪前化疗时代开始以来一直限制着癌症患者的生存。尽管将干细胞 (SC) 概念应用于癌症在多年来激发了科学家的想象力，但直到最近十年才产生了大量证据表明癌症干细胞 (CSC) 有助于化疗耐药性。最近的研究表明，CSC 的功能和分子特性为提高化疗疗效提供了治疗机会。在这里，我们回顾了这些特性如何刺激了一系列恶性肿瘤中抑制获得性耐药性的联合策略。这些策略的临床实施有望为应对这一持久挑战注入新的活力。
